



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Medara, N;Lenzo, JC;Walsh, KA;Holden, JA;Reynolds, EC;Darby, IB;O'Brien-Simpson, NM

Title:

Peripheral memory T-cell profile is modified in patients undergoing periodontal management

Date:

2021-02-01

Citation:

Medara, N., Lenzo, J. C., Walsh, K. A., Holden, J. A., Reynolds, E. C., Darby, I. B. & O'Brien-Simpson, N. M. (2021). Peripheral memory T-cell profile is modified in patients undergoing periodontal management. *Journal of Clinical Periodontology*, 48 (2), pp.249-262. <https://doi.org/10.1111/jcpe.13399>.

Persistent Link:

<https://hdl.handle.net/11343/276638>

DR. NIDHI MEDARA (Orcid ID : 0000-0002-5450-0647)

PROF. ERIC REYNOLDS (Orcid ID : 0000-0002-6618-4856)

Article type : Original Article Clinical Periodontology

## Peripheral memory T-cell profile is modified in patients undergoing periodontal management

Nidhi Medara<sup>1</sup>, Jason C. Lenzo<sup>1,2</sup>, Katrina A. Walsh<sup>3</sup>, James A. Holden<sup>1,2</sup>, Eric C. Reynolds<sup>1,2\*</sup>, Ivan B. Darby<sup>1\*</sup>, and Neil M. O'Brien-Simpson<sup>1,2\*</sup>

<sup>1</sup> Melbourne Dental School, The University of Melbourne, 720 Swanston Street, Carlton, VIC 3053, Australia

<sup>2</sup> The Centre for Oral Health Research, The University of Melbourne, 720 Swanston Street, Carlton, VIC 3053, Australia

<sup>3</sup> Austin Hospital, 145 Studley Rd, Heidelberg, VIC 3084, Australia.

\*Corresponding authors

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/JCPE.13399](https://doi.org/10.1111/JCPE.13399)

This article is protected by copyright. All rights reserved

## ADDRESS FOR CORRESPONDENCE

Prof Neil M. O'Brien-Simpson, Centre for Oral Health Research, The University of Melbourne, 720 Swanston Street, Carlton, VIC 3053, Australia. ORCID ID: 0000-0001-8462-5603. Email: neil.obs@unimelb.edu.au

Prof Ivan B. Darby, Melbourne Dental School, The University of Melbourne, 720 Swanston Street, Carlton, VIC 3053, Australia. ORCID ID: 0000-0002-6457-5327. Email: idarby@unimelb.edu.au

Prof Eric C. Reynolds, Centre for Oral Health Research, The University of Melbourne, 720 Swanston Street, Carlton, VIC 3053, Australia. ORCID ID: 0000-0002-6618-4856. Email: e.reynolds@unimelb.edu.au

## RUNNING TITLE

Memory T-cells & Periodontitis

## CONFLICT OF INTEREST AND FUNDING INFORMATION

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

This study was supported by grants from the Australian National Health and Medical Research Council (APP1029878) and the Australian Dental Research Foundation (ADRF, 120-2016).

## ACKNOWLEDGEMENTS

The authors wish to acknowledge the Melbourne Cytometry Platform for use of their equipment and expertise.

The Australian National Health and Medical Research Council (NHMRC) of Australia and Australian Research Council (ARC) are thanked for financial support over many years for the immunology studies reported in the authors' laboratories. NMOBS is the recipient of NHMRC funding (APP1142472, APP1158841, APP1185426), ARC funding (DP160101312, LE200100163), Cancer Council Victoria funding (APP1163284) and ADRF in immunology and research is supported by the

Centre for Oral Health Research at The Melbourne Dental School. NM was supported by the Oral Health Cooperative Research Centre Top-up Scholarship.

## ABSTRACT

**Aims:** T-cells are known to have a role in periodontitis, however, the effect of periodontal therapy on peripheral memory T-cells is unclear. This study evaluated variation in peripheral memory T-cells and red complex bacteria in sub-gingival plaque in patients undergoing periodontal management.

**Methods:** Peripheral blood mononuclear cells and sub-gingival plaque were collected from 54 periodontitis patients at baseline, 3-, 6- and 12-months post-therapy and 40 healthy controls. Periodontitis patients were divided into treatment outcome (TxO) groups based on prevalence of sites with probing depth  $\geq 5$ mm as good (<10% of sites), moderate (10-20%) or poor (>20%) at study conclusion. Naïve ( $T_N$  – CCR7<sup>+</sup>CD45RA<sup>+</sup>), central memory ( $T_{CM}$  – CCR7<sup>+</sup>CD45RA<sup>-</sup>), effector memory ( $T_{EM}$  – CCR7<sup>-</sup>CD45RA<sup>-</sup>) and effector memory T-cells re-expressing CD45RA ( $T_{EMRA}$  – CCR7<sup>-</sup>CD45RA<sup>+</sup>) were phenotyped using flow cytometry in CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup>CD8<sup>+</sup> and CD4<sup>-</sup>CD8<sup>-</sup> T-cells and red complex bacteria were quantified using qPCR.

**Results:** At baseline, periodontitis subjects had significantly greater mean probing depths and *P. gingivalis* proportions, lower  $T_N$  but higher CD4<sup>+</sup>  $T_{CM}$ , CD8<sup>+</sup>  $T_{CM}$ , CD4<sup>+</sup>CD8<sup>+</sup>  $T_{EM}$ , and CD4<sup>-</sup>CD8<sup>-</sup>  $T_{EM}$  cell proportions compared to health. Periodontal therapy decreased mean probing depths, *P. gingivalis* proportions,  $T_{EM}$  and CD4<sup>+</sup> and CD8<sup>+</sup>  $T_{CM}$  cells, but increased  $T_N$  and CD4<sup>+</sup> and CD8<sup>+</sup>  $T_{EMRA}$  cells. The T-cell profile in the good TxO group showed therapy-related changes in CD4<sup>+</sup>  $T_{EM}$ , and CD8<sup>+</sup>  $T_N$  and  $T_{EM}$  cells, whereas, no changes were observed in the poor TxO group.

**Conclusion:** Management and the reduction in red complex bacteria were associated with changes in peripheral memory T-cells in periodontitis.

**Keywords:** T-lymphocytes, immunologic memory, periodontitis, disease management, host-pathogen interactions

## CLINICAL RELEVANCE

**Scientific rationale:** Immunological memory an important feature of adaptive immunity and the peripheral memory T-cell profile in periodontitis is not well characterised in response to periodontal management. This study examined the effect of periodontal therapy including scaling and root debridement and, if indicated, additional access flap surgery on four memory T-cell phenotypes in CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup>CD8<sup>+</sup> and CD4<sup>+</sup>CD8<sup>-</sup> cells over one year in periodontitis patients.

**Principal findings:** Naïve T-cells increased, whereas effector memory and CD4<sup>+</sup> and CD8<sup>+</sup> central memory T-cells decreased with therapy. CD4<sup>+</sup> effector memory and CD8<sup>+</sup> naïve and effector memory T-cells showed changes with therapy in the good treatment outcome group but not in the poor.

**Practical implications:** Our findings suggest that conventional periodontal management does have an effect on peripheral memory T-cells in periodontitis. Moreover, this effect is only seen in the good treatment outcome group in some memory cells subsets suggesting that those who have more sites with deeper probing depths at the end of management do not show an underlying change in immune response. Understanding the peripheral memory T-cell response in the pathogenesis of periodontitis may lead to better disease management and identification of novel T-cell based diagnostics and therapies that clinicians can use to monitor management and provide on-going strategies to improve patients' periodontal health.

## INTRODUCTION

Periodontitis is a multifactorial disease associated with a dysbiotic biofilm and a chronic dysregulated immune-inflammatory response. T-cells are a major subset of adaptive immunity that play a central role in periodontitis (Fujihashi et al. 1996). One distinguishing feature of adaptive immunity is immunological memory which enables a rapid and efficient response to previously encountered pathogens or antigens (Farber et al. 2016).

The surface expression of cellular markers restricts migration through specific tissues and facilitates functional phenotyping of memory cells. Based on the expression of CCR7 and CD45RA, memory T-cells can be phenotyped as naïve (T<sub>N</sub> – CCR7<sup>+</sup>CD45RA<sup>+</sup>), effector memory T-cells re-expressing

CD45RA (T<sub>EMRA</sub> – CCR7<sup>-</sup>CD45RA<sup>+</sup>), central memory (T<sub>CM</sub> – CCR7<sup>+</sup>CD45RA<sup>-</sup>) and effector memory (T<sub>EM</sub> – CCR7<sup>-</sup>CD45RA<sup>-</sup>) T-cells (Sallusto et al. 1999). Antigen-inexperienced T<sub>N</sub> cells recirculate between secondary lymphoid organs and blood. They are long-lived but display a restricted cytokine profile. Upon activation, T<sub>N</sub> cells undergo expansion and differentiate into effector cells with potent pathogen-eliminating functions. T<sub>CM</sub> cells preferentially home to secondary lymphoid organs. They are characterized by low effector function, but have high proliferative capacity and reduced need for co-stimulation compared to T<sub>N</sub> cells. Upon antigenic stimulation, T<sub>CM</sub> cells are converted to T<sub>EM</sub> cells which preferentially home to peripheral sites and display rapid effector function, but have poor proliferative capacity. Most T<sub>EM</sub> cells are CD45RA<sup>-</sup>, however, a subset re-express CD45RA and are termed T<sub>EMRA</sub> cells. T<sub>EMRA</sub> cells are more terminally differentiated compared to T<sub>CM</sub> and T<sub>EM</sub> cells (Harari et al. 2004) with poor proliferative potential, but high cytotoxicity and sensitivity to apoptosis (Geginat et al. 2003; Hamann et al. 1997).

Memory T-cell profiles in peripheral blood in response to therapy are not well established in periodontitis. Previously, CD4<sup>+</sup>CD45RA<sup>+</sup> naïve (Afar et al. 1992) and CD4<sup>+</sup>CD45RO<sup>+</sup> antigen-experienced memory cells (Afar et al. 1992; Aoyagi et al. 1995) were reported to be higher in periodontitis, whereas others reported that neither CD4<sup>+</sup>CD45RA<sup>+</sup> naïve (Seymour et al. 1997) nor CD4<sup>+</sup>CD45RO<sup>+</sup> memory cells (Cheng et al. 2018) were significantly different in chronic or aggressive periodontitis compared to health. Longitudinal studies have reported significantly increased CD4<sup>+</sup>CD45RA<sup>+</sup> naïve cells post-treatment (Kimura et al. 1991).

The immune-inflammatory response in periodontitis may be subverted by keystone pathogens and over-activated by pathobionts in a synergistic polymicrobial community. *Porphyromonas gingivalis* represents a keystone pathogen in periodontitis causing microbial and immune dysbiosis through its virulence factors and ability to subvert the host's immune response (Hajishengallis et al. 2011). *P. gingivalis* is often closely localised with *Treponema denticola* and *Tannerella forsythia*, together termed the red complex bacteria, which have been reported to be strongly associated with clinical parameters of periodontitis (Socransky et al. 1998).

There is mounting evidence that local microbial dysbiosis and ensuing immune response in periodontitis may have distant systemic effects (Chapple and Genco 2013; Tonetti and Van Dyke 2013). This may be mediated by the leakage of microbial and inflammatory products into systemic circulation via the ulcerated and highly vascularised oral epithelial barrier in diseased states (Konkel et al. 2019). The effect of periodontal management and memory T-cells in peripheral blood needs further investigation. The primary aim of this study was to evaluate management-related variation

of peripheral  $T_N$ ,  $T_{EMRA}$ ,  $T_{CM}$  and  $T_{EM}$  cells in  $CD4^+$ ,  $CD8^+$ ,  $CD4^+CD8^+$  and  $CD4^-CD8^-$  populations and red complex bacteria proportions in sub-gingival plaque. The secondary aim was to investigate whether there were differences based on response to management. An understanding of the memory T-cell response to therapy could provide insight into the underlying host response in periodontitis and will aid in better disease management strategies.

## MATERIALS AND METHODS

### Study protocol

The Human Ethics Sub-Committee, The University of Melbourne (1339812.3) and Human Ethics Research Committee, Dental Health Services Victoria (279) approved the study. Sample size calculations were based on previously published work by the same group (Byrne et al. 2009) and were calculated for a parent study on T helper cells which considered a significant decrease of 2.25% in  $IL-17^+$  cells (Zhao et al. 2011). At  $\alpha=0.05\%$  and power of 0.85%, 38 patients were required in periodontitis arm which was rounded up to 40. To account for attrition rate of 20%, 50 subjects were required in the periodontitis group. Informed written consent was gained from each participant at study commencement. Data collection took place between 2015-2017. The study design and recruitment process are displayed in appendix figure 1 and conforms to the STROBE guidelines.

Periodontitis subjects ( $n=54$ ) were recruited from the specialist periodontics clinic at The Royal Dental Hospital of Melbourne and Melbourne Dental Clinic, The University of Melbourne. The inclusion criteria for periodontitis subjects were at least two non-adjacent sites per quadrant exhibiting probing depths (PD)  $\geq 5$ mm, excluding the third molars (Darby et al. 2001). Subjects were  $>21$  years, had a minimum of 16 teeth (excluding the third molars) and were systemically healthy with no periodontal therapy or antibiotic use within the preceding 6 months (appendix tables 1, 2). Exclusion criteria included pregnancy or lactation and medical conditions affecting the progression of periodontitis (e.g. diabetes) or requiring pre-medication prior to management.

For the control group ( $n=40$ ), the inclusion criteria were a gender and age ( $\pm 5$  years) match to the periodontitis subject with no PD  $>4$ mm or percentage of sites with bleeding on probing (%BOP)  $>30\%$ . The remaining inclusion and exclusion criteria were the same as for the periodontitis subject.

The periodontal parameters, mean PD and %BOP, sub-gingival plaque and blood were collected from periodontitis subjects at baseline before therapy and at 3-, 6- and 12-months post-therapy. PD and

BOP were recorded at six sites around each tooth using William's probe (Hu-Friedy Mfg. Co., Chicago, USA). PD was rounded up to the nearest millimeter from the base of the gingival sulcus to the free gingival margin. BOP was assessed visually following probing to the base of the sulcus and recorded as present or absent up to 30 seconds after probing. Smoking status was defined as current smoker or non-smoker at study commencement.

Periodontal management involved patient education and oral hygiene instructions (OHI) prior to non-surgical quadrant scaling and root debridement usually over a period of 4 weeks. They were re-evaluated at 3-, 6-, 9- and 12-months. At re-evaluation, clinical parameter were charted, the outcome of therapy evaluated, patients given OHI as needed, and residual pockets re-debrided or access flap surgery performed ( $n=5$ ) as necessary. The management goal was PD <4mm and %BOP <30%.

At the end of one year or when periodontitis patients exited the study, they were assigned to a treatment outcome (TxO) group where the good TxO group had <10%, moderate TxO group had between 10-20%, and poor TxO group had >20% of sites with PD  $\geq$ 5mm.

### Memory T-cell phenotyping

Peripheral blood was collected in potassium-EDTA tubes (BD Biosciences, NSW, Australia) and peripheral blood mononuclear cells (PBMCs) were obtained by density-gradient centrifugation using Histopaque-1077 (Sigma-Aldrich, NSW, Australia) following manufacture's instruction. Fresh PBMCs ( $1 \times 10^6$  cells/100 $\mu$ L) were incubated for 30 minutes at 4 $^{\circ}$ C with pre-diluted antibodies against CD45-APC (1 $\mu$ L, clone – HI30), CD4-APCCy7 (1 $\mu$ L, clone – RPA-T4), CD8-AF488 (5 $\mu$ L, clone – RPA-T8), TCR $\alpha\beta$ -BV785 (2 $\mu$ L, clone – T10B9.1A-31), CD45RA-PECy7 (0.5 $\mu$ L, clone – L48) and CCR7-PE (10 $\mu$ L, clone – 150503). Antibodies were purchased from BD Bioscience and volumes used were optimised based on manufacture's recommendation. After incubation, PBMCs were washed twice with 2mL FACS wash (2% w/v BSA, 2mM EDTA, 0.02% v/v sodium azide in PBS) by centrifugation at 800RCF, 5 minutes, 4 $^{\circ}$ C and resuspended in 200 $\mu$ L FACS wash for acquisition on BD LSRFortessa™ X-20. Unstained and single antibody-stained PBMCs were used as controls for each sample. Data analysis was performed using FlowJo (v10, Tree Star Inc., OR, USA).

## Sub-gingival plaque collection and quantification of red complex bacteria

Sub-gingival plaque from the same site was used for analysis in the periodontitis subject. Site selection criterion for the periodontitis subject was a tooth with PD  $\geq$ 5mm and for the control subject, a tooth with PD  $\leq$ 3mm. The exclusion criteria for both groups were mobility  $\geq$ grade 2, pulp or periapical diseases and teeth subject to occlusal trauma or inadequate prosthetic restorations.

For plaque collection, the respective tooth surface was isolated with cotton rolls, gently air-dried and supra-gingival plaque removed with a sterile curette. A sterile Gracey curette (Hu-Friedy) was inserted as deep as possible into the gingival sulcus without applying pressure to the tooth surface. The plaque sample was collected with a single vertical stroke and immediately placed into 300 $\mu$ L TE buffer (10mM tris(hydroxymethyl)-methylamine chloride, 1mM EDTA (pH 7.4)) and stored at -80°C until processing.

*P. gingivalis* (F – AGGCAGCTTGCCATACTGCG; R – ACTGTTAGCAACTACCGATGT), *T. denticola* (F – TAATACCGAATGTGCTCATTACAT; R – TCAAAGAAGCATTCCCTCTTCTTCTTA), *T. forsythia* (F – AAAACAGGGGTTCCGCATGG; R – TTCACCGCGGACTTAACAGC) and total bacteria (F – GATTAGATACCC TGGTAGTCCAC; R – CCCGGAACGTATTCACCG) were quantified by qPCR (appendix material and methods). Values are reported as a proportion of total bacteria.

## Statistical analysis

Independent samples *t*-tests with unequal variances were used for comparisons between health and periodontitis at each timepoint. Linear mixed models (LMMs) were used to determine changes in the mean of the outcome variable over timepoint and TxO group in periodontitis. The base model for variations over timepoint included timepoint, age and gender as fixed effects and subject as random effect. The base model for variations over TxO group included TxO group, timepoint, interaction between TxO group and timepoint, age and gender as fixed effects and subject as random effect. Pairwise comparisons of estimated marginal means were used to assess significant differences.

Independent samples *t*-test with unequal variance were used to assess differences between smokers and non-smokers at each timepoint. The interaction of smoking and timepoint, and smoking and TxO group were also added as fixed effects to the base LMMs.

Paired samples *t*-tests were used for comparison of red complex bacteria and memory T-cells within each timepoint. Spearman's correlations were used for associations with the periodontal parameters, memory T-cells and red complex bacteria at each timepoint.

The significance level was set at  $p \leq 0.05$  for all variables. All statistical analyses were performed in SPSS (v23, IBM Corp., NY, USA) and graphs prepared using GraphPad Prism (v5, GraphPad Software, CA, USA).

## RESULTS

### Periodontal parameters

The cohort demographics and periodontal parameter are displayed in table 1. No significant differences were observed in gender, age and smoking status between health and baseline, however, the healthy cohort had significantly more teeth. Of the 54 subjects at baseline, 6 achieved the management goal of no PD  $\geq 4$ mm and %BOP  $> 30\%$ .

Mean PD and %BOP were significantly higher in periodontitis compared to health, and decreased significantly at subsequent timepoints compared to baseline.

Periodontitis subjects ( $n=8$ ) who only contributed to baseline were not assigned to a TxO group. Mean PD was significantly different at baseline and 12-months between the three TxO groups, with the poor TxO group showing higher mean PD followed by moderate and good groups. %BOP was not significantly different between the TxO groups at baseline, however, %BOP was significantly higher in the poor compared to the good TxO group post-therapy.

Smokers displayed significantly less %BOP (mean difference ( $d$ ) = 22.35%) at baseline and deeper mean PD ( $d=0.40$ mm) at 3-months compared to non-smokers. At baseline in the moderate TxO group, mean PD ( $d=0.75$ mm) and %BOP ( $d=43.72\%$ ) were significantly lower in smokers compared to non-smokers. The interaction between smoking and timepoint was a predictor for %BOP at baseline at  $p=0.056$  (estimate of fixed effect ( $b$ )=29.03, standard error (SE)=2.91), where smokers had 29.03% less %BOP compared to non-smokers. The interaction between smoking and TxO group was also a significant predictor for %BOP in the good ( $b=-32.54$ , SE=12.99) and moderate ( $b=-33.07$ , SE=10.59) TxO groups where BOP increased as the TxO group worsened from good to moderate and smokers had significantly less %BOP in the good and moderate TxO groups compared to non-smokers.

## Memory T-cells

The gating strategy to phenotype memory T-cells is displayed in figure 1. T-cell populations and their memory subsets in relation to each other are displayed in appendix figure 2. CD4<sup>+</sup>CD8<sup>+</sup> memory cells exhibited a similar profile to CD4<sup>+</sup> cells which had a small T<sub>EMRA</sub> and large T<sub>CM</sub> cell proportions, whereas CD4<sup>+</sup>CD8<sup>-</sup> memory cells were similar to CD8<sup>+</sup> cells which had a large T<sub>EMRA</sub> and small T<sub>CM</sub> cell proportions.

CD4<sup>+</sup> T<sub>N</sub>, CD4<sup>+</sup>CD8<sup>+</sup> T<sub>N</sub>, CD4<sup>-</sup>CD8<sup>-</sup> T<sub>N</sub> and CD4<sup>+</sup>CD8<sup>+</sup> T<sub>EMRA</sub> cells were lower, whereas total CD4<sup>+</sup>CD8<sup>+</sup>, CD4<sup>+</sup> T<sub>CM</sub>, CD8<sup>+</sup> T<sub>CM</sub>, CD4<sup>+</sup>CD8<sup>+</sup> T<sub>EM</sub> and CD4<sup>-</sup>CD8<sup>-</sup> T<sub>EM</sub> cells were higher at baseline compared to health (figure 2). Overall, periodontal therapy resulted in an increase in T<sub>N</sub> cells in all four subsets and T<sub>EMRA</sub> cells in CD4<sup>+</sup>, CD8<sup>+</sup> and CD4<sup>+</sup>CD8<sup>+</sup> cell subsets, whereas T<sub>EM</sub> cells in all four subsets, and CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>CM</sub> cells decreased.

Memory T-cells separated based on TxO groups are displayed in figure 3 and appendix figures 3–6. CD8<sup>+</sup> T<sub>N</sub> cells were significantly increased post-therapy in the good group, but showed no therapy-related changes in the poor TxO group. Likewise, CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>EM</sub> cells displayed a significant therapy-related reduction in the good group, but no differences were observed in the poor TxO group.

Smokers had significantly more CD8<sup>+</sup> T<sub>N</sub> ( $d=12.32\%$ ) and fewer CD8<sup>+</sup> T<sub>EMRA</sub> ( $d=11.61\%$ ) cells at baseline, and more CD4<sup>+</sup> T<sub>N</sub> ( $d=11.90\%$ ) and fewer CD4<sup>+</sup> T<sub>EMRA</sub> ( $d=0.65\%$ ), CD4<sup>+</sup> T<sub>CM</sub> ( $d=6.05\%$ ), CD4<sup>+</sup> T<sub>EM</sub> ( $d=5.14\%$ ) and CD4<sup>+</sup>CD8<sup>+</sup> T<sub>CM</sub> ( $d=9.67\%$ ) cells at 6-months compared to non-smokers. The interaction between smoking and timepoint was a significant predictor for CD8<sup>+</sup> T<sub>EMRA</sub> cells at 3- ( $b=8.00$ ,  $SE=4.00$ ) and 6-months ( $b=10.59$ ,  $SE=4.03$ ) where they were significantly higher in smokers compared to non-smokers.

## Red complex bacteria

At baseline, *P. gingivalis* proportions were significantly higher than *T. denticola* and *T. forsythia* (appendix figure 7). *P. gingivalis* and *T. denticola* were significantly higher at baseline compared to health and decreased post-therapy (table 2). All three bacteria were recovered from a significantly greater number of sites at all timepoints in periodontitis compared to health, however, no difference were observed in bacterial recovery in the periodontitis group post-therapy.

When separated into TxO groups (figure 4), *P. gingivalis* was significantly decreased at 3- and 12-months post-therapy compared to baseline within all three TxO groups, however, only the poor TxO group had a significantly higher proportion of *P. gingivalis* at baseline compared to health.

Associations between periodontal parameters, memory T-cells and red complex bacteria

Periodontal parameters were correlated with each other (table 1), memory T-cells (table 3) and red complex bacteria (table 2). Memory T-cells were also correlated with red complex bacteria (appendix table 6).

When %BOP was added to the base LMM as a fixed effect, it was a significant predictor for mean PD ( $b=0.01$ ,  $SE=0.00(1)$ ) with both timepoint and TxO group. Likewise, mean PD was a significant predictor for %BOP with timepoint ( $b=29.03$ ,  $SE=2.91$ ) and TxO group ( $b=30.74$ ,  $SE=3.19$ ).

When mean PD and %BOP were added to the base LMMs, both mean PD and %BOP were significant predictors for  $CD8^+ T_{CM}$  and  $CD8^+ T_{EM}$  cells in the model for timepoint. For a 1mm increase in mean PD,  $CD8^+ T_{CM}$  cells ( $b=2.65$ ,  $SE=1.25$ ) increased by 2.65% and  $CD8^+ T_{EM}$  cells ( $b=-5.66$ ,  $SE=2.82$ ) decreased by 5.66%. Likewise, for a 1% increase in %BOP,  $CD8^+ T_{CM}$  cells ( $b=-0.08$ ,  $SE=0.03$ ) decreased by 0.08% and  $CD8^+ T_{EM}$  cells ( $b=0.21$ ,  $SE=0.06$ ) increased by 0.21%. Upon separation into TxO groups, mean PD was a significant predictor for  $CD8^+ T_N$  ( $b=-0.15$ ,  $SE=0.07$ ) and  $CD8^+ T_{EM}$  ( $b=-9.16$ ,  $SE=3.09$ ) cells, and %BOP for  $CD8^+ T_{CM}$  ( $b=-0.08$ ,  $SE=0.03$ ) and  $CD8^+ T_{EM}$  ( $b=0.22$ ,  $SE=0.06$ ) cells. Mean PD was a significant predictor for *T. forsythia* with both timepoint ( $b=0.29$ ,  $SE=0.14$ ) and TxO ( $b=0.40$ ,  $SE=0.19$ ).

When all red complex bacteria were included as fixed effects in the base LMMs, *P. gingivalis* was a significant predictor for  $CD8^+ T_{CM}$  ( $b=-0.05$ ,  $SE=0.03$ ) and  $CD4^+ CD8^- T_{EM}$  ( $b=-0.17$ ,  $SE=0.08$ ) cells for timepoint.

## DISCUSSION

The main goal of periodontal therapy is to establish clinically healthy periodontal conditions. Given that these are manifested as shallow pockets that do not bleed when probed, mean PD and %BOP were used as clinical parameters of periodontitis in this study. Periodontal therapy is an effective

means for disease management. However, response to treatment varies considerably between patients and treatment sites making the assessment of overall response in a patient methodologically problematic (Badersten et al. 1981; 1984; Lindhe et al. 1984; Pihlstrom et al. 1983). Thus, in addition to assessing mean PD and %BOP as a measure of response to management, this study also used the prevalence of sites that exhibited PD  $\geq 5$ mm as a more clinically relevant measure of assessing overall treatment outcome. This was based on a previous study that described poor responders as having  $>10\%$  of sites with PD  $>4$ mm and %BOP  $\geq 20\%$  after one year of active treatment (Holmlund et al. 2017). However, unlike the study by Holmlund *et al.*, %BOP was not used to define TxO groups in this study as mean %BOP at 12-months exceeded  $\geq 20\%$  and %BOP was significantly associated with mean PD with both Spearman's correlations and LMMs. Moreover, a moderate TxO group with 10-20% of sites with PD  $\geq 5$ mm was also included as it was felt that this group was masking the effects of the poor TxO group. Accordingly, mean PD was significantly different between the three TxO groups at baseline and 12-months. Previous studies have also reported other ways of evaluating response to periodontal therapy (Badersten et al. 1985; Haffajee et al. 1997; Hughes et al. 2006; Sexton et al. 2011).

The proportion of  $T_N$  cells in all four T-cells subsets was lower at baseline compared to health (although not significant in  $CD8^+$  cells,  $CD8^+ T_N$  cells were 6.8% lower at baseline). This suggests that within circulating PBMCs, there are significantly more T-cells of all subsets that are of a memory phenotype in periodontitis patients compared to healthy controls. At 12-months post-therapy,  $T_N$  cells were significantly increased in all four T-cell populations. This increase in  $T_N$  cells was also reflected when separated into TxO groups, where the greatest increase from baseline to 12-months was evident in the good TxO group for  $CD4^+$  and  $CD8^+$  cells. This may be due to active differentiation of  $T_N$  cells into effector and/or memory cells by periodontal antigens before therapy at baseline. Periodontal therapy reduces bacterial load and this may decrease active differentiation of  $T_N$  cells restoring levels to that seen in health. This is coincident with the findings that the greatest reduction in mean PD and *P. gingivalis* proportions occurred between baseline and 3-months and  $T_N$  cell levels were restored to those similar in health in  $CD4^+$ ,  $CD4^+CD8^+$  and  $CD4^-CD8^-$  cells at 3-months post-therapy. However, as this study did not evaluate the specificity of T-cells these results should be interpreted with caution and future studies investigating periodontopathogen-specific memory T-cells are needed.

$T_{CM}$  and  $T_{EM}$  cells have complimentary functions where  $T_{EM}$  cells homing to peripheral tissues mount a rapid initial response to check the replication and spread of invading pathogens, whereas  $T_{CM}$  cells mount a robust response and can undergo rapid proliferation and differentiation (Sallusto et al.

2004). Thus, it follows that these rapidly proliferating CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>CM</sub> cells were significantly higher at baseline possibly in response to the systemic dissemination of periodontal antigens. The different migration capabilities of T<sub>CM</sub> and T<sub>EM</sub> cells may also account for this differences where CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>CM</sub> cells and not CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>EM</sub> cell were higher at baseline. T<sub>EM</sub> cells may be increased at barrier sites, and indeed a study in healthy gingival tissues found higher CD8<sup>+</sup> T<sub>EM</sub> cells compared to CD8<sup>+</sup> T<sub>CM</sub> cells (Dutzan et al. 2016). The functional differences in CD4<sup>+</sup> T helper cells, which orchestrate the immune response, and CD8<sup>+</sup> T cytotoxic cells, which have more direct effector functions, may also affect T<sub>CM</sub> and T<sub>EM</sub> cell distribution in peripheral blood. Accordingly, there were higher proportions of CD4<sup>+</sup> T<sub>CM</sub> and lower T<sub>EM</sub> cells, and higher CD8<sup>+</sup> T<sub>EMRA</sub> and T<sub>EM</sub> and lower T<sub>CM</sub> cells in peripheral circulation. In this study, CD8<sup>+</sup> T<sub>CM</sub> cells were negatively associated with *P. gingivalis*, and CD8<sup>+</sup> cells may play an important adjuvant role to that of the dominant CD4<sup>+</sup> response. Interestingly, a small proportion of CD4<sup>+</sup>CD8<sup>+</sup> and CD4<sup>-</sup>CD8<sup>-</sup> T<sub>EM</sub> cells were significantly higher at baseline and decreased post-therapy and may represent a population with more immediate effector function (Weiss et al. 1998). In contrast, a study found similar proportions of CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>CM</sub> and T<sub>EM</sub> cells in gingival tissues in periodontitis and health (Mahanonda et al. 2018). Moreover, peripheral blood only contains 2-3% of total T-cell pool (Di Rosa and Pabst 2005), and may not be representative of memory phenotypes found at sites of disease activity. This preferential localization is to be expected, as it is more likely that microbes are encountered at barrier sites. In addition, as this study phenotyped memory T-cells based on the expression receptors which restricts entry into specific tissues such as the secondary lymphoid organs (CCR7), this may not necessarily translate to periodontal tissue infiltration.

Bacterial quantification in this study found that while the prevalence of red complex bacteria generally decreased with therapy, the detection rate remained unchanged. High detection rates and persistence following management is in agreement with previous studies (Ehmke et al. 2005) and indicates that the mere presence of virulent bacteria may not be indicative of a pathological clinical situation. This is in line with the currently held concepts of “polymicrobial synergy and dysbiosis” (Hajishengallis et al. 2012) and the newer “inflammation-mediated polymicrobial-emergence and dysbiotic-exacerbation (IMPEDE)” (Van Dyke et al. 2020) in the pathogenesis of periodontitis where the shift to a dysbiotic microflora occurs largely due to excessive and non-resolving inflammation leading to pocket formation and favourable bacterial growth conditions. The trend for decreasing proportions of *P. gingivalis* following therapy was consistent over time, except for an increase at 6-months. This was due to high proportions measured in four patients (83.60% – moderate TxO, 44.02% – poor TxO, 31.46% – good TxO and 24.67% – poor TxO), which increased the group mean with wide standard deviations. Separating periodontitis based on clinical responses showed higher *P.*

*gingivalis* proportions at baseline only in the poor TxO group. The poor TxO group displayed higher mean PD at baseline and deeper pockets may serve as a more conducive environment for effective bacterial growth. Deeper pockets pose difficulties with gaining access and thus are harder to manage efficaciously. Previous studies have observed that pockets with deeper PD have increased plaque and calculus still remaining after instrumentation (Adriaens and Adriaens 2004).

Smoking did not have an effect on red complex bacteria in this study. However, in general, smokers had higher  $T_N$  and lower  $T_{EM}$  and  $T_{EMRA}$  cell proportions compared to non-smokers. Higher  $CD4^+CD45RA^+$  naïve and lower  $CD4^+CD45RO^+$  memory cells in heavy smokers compared to non-smokers were reported in a previous study in healthy adults (Tanigawa et al. 1998). The reason for this unknown, but smoking may impair the functional potential of  $CD4^+$  cells leading to decreased generation of effector memory populations (Tejero et al. 2018) and increased persistence of naïve cells (Tanigawa et al. 1998). In contrast, other studies have observed higher  $CD4^+CD45RA^+$  naïve and  $CD4^+CD45RO^+$  memory cells (Schaberg et al. 1997; Vardavas et al. 2010) or no differences in memory T-cells in smokers compared to non-smokers (Chavance et al. 1993). Due to the limited sample size in this study, the effects of smoking on memory T-cells should be interpreted cautiously and warrants further investigation.

Previous literature has used other cell surface marker expression such as CD28, CD29, CD31, CD44, CD45RO, CD62L and CD69 to phenotype memory T-cells (van den Broek et al. 2018). It is unclear at this stage if the combination of markers used identify naïve and memory cell populations are consistent between studies. The roles of  $T_{CM}$  and  $T_{EM}$  cells may be fluid and their precise effector roles need investigation. Some research has been undertaken into skin and gut homing receptors for memory T-cells (Mora and von Andrian 2006), however, gingival homing receptors are yet to be elucidated. The longitudinal nature of the study partly accounts for temporal biological variation, such as underlying chronic medical conditions or medication use (appendix tables 1, 2), and provides information on the short and medium-term effects of periodontal therapy. However, while the sample size at baseline exceeded the number of subjects required to have sufficiently acceptable statistical power, there was a reduction in sample size (31.5%) at 12-months due to dropouts. Furthermore, separation into TxO groups essentially divided the sample size at each timepoint by one-third. This may increase type II error and thus, future studies with larger sample size acquired from multiple locations would increase the reliability of these results. T-cell memory is an evolving field and recently tissue-resident (Gebhardt et al. 2009), stem cell (Gattinoni et al. 2009), peripheral (Gerlach et al. 2016) and virtual (Marusina et al. 2017) memory T-cells have also been identified. Moreover, innate cells such as natural killer cells and macrophages are also thought to have

immunological memory (Pradeu and Du Pasquier 2018). These different memory cell subsets may have distinct roles in chronic inflammation and further studies are required to elucidate their role in periodontitis.

To our knowledge, this is the first study that phenotypes longitudinal variation in peripheral T<sub>N</sub>, T<sub>EMRA</sub>, T<sub>CM</sub> and T<sub>EM</sub> cells in periodontitis based on CCR7 and CD45RA expression. This study showed that conventional periodontal therapy does impact peripheral memory T-cells, and in some cell subsets such as CD8<sup>+</sup> T<sub>N</sub> and CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>EM</sub> cells this variation with treatment may be dependent on the response to treatment. Overall, these findings provide new insight into the changing phenotype of memory T-cells in response to therapy in periodontitis.

## REFERENCES

- Adriaens PA, Adriaens LM. 2004. Effects of nonsurgical periodontal therapy on hard and soft tissues. *Periodontol 2000*. 36:121-145.
- Afar B, Engel D, Clark EA. 1992. Activated lymphocyte subsets in adult periodontitis. *J Periodontal Res*. 27(2):126-133.
- Aoyagi T, Sugawara-Aoyagi M, Yamazaki K, Hara K. 1995. Interleukin 4 (il-4) and il-6-producing memory t-cells in peripheral blood and gingival tissues in periodontitis patients with high serum antibody titers to porphyromonas gingivalis. *Oral Microbiol Immunol*. 10(5):304-310.
- Badersten A, Nilveus R, Egelberg J. 1981. Effect of nonsurgical periodontal therapy. I. Moderately advanced periodontitis. *J Clin Periodontol*. 8(1):57-72.
- Badersten A, Nilveus R, Egelberg J. 1984. Effect of nonsurgical periodontal therapy. li. Severely advanced periodontitis. *J Clin Periodontol*. 11(1):63-76.
- Badersten A, Nilveus R, Egelberg J. 1985. Effect of nonsurgical periodontal therapy. V. Patterns of probing attachment loss in non-responding sites. *J Clin Periodontol*. 12(4):270-282.
- Byrne S, Dashper S, Darby I, Adams G, Hoffmann B, Reynolds E. 2009. Progression of chronic periodontitis can be predicted by the levels of porphyromonas gingivalis and treponema denticola in subgingival plaque. *Oral Microbiol Immunol*. 24(6):469-477.
- Chapple IL, Genco R. 2013. Diabetes and periodontal diseases: Consensus report of the joint efp/aap workshop on periodontitis and systemic diseases. *J Periodontol*. 84(4 Suppl):S106-112.

- Chavance M, Perrot JY, Annesi I. 1993. Smoking, cd45r0+ (memory), and cd45ra+ (naive) cd4+ t cells. *Am Rev Respir Dis.* 148(1):237-240.
- Cheng WC, Saleh F, Abuaisa Karim B, Hughes FJ, Taams LS. 2018. Comparative analysis of immune cell subsets in peripheral blood from patients with periodontal disease and healthy controls. *Clin Exp Immunol.* 194(3):380-390.
- Darby IB, Mooney J, Kinane DF. 2001. Changes in subgingival microflora and humoral immune response following periodontal therapy. *J Clin Periodontol.* 28(8):796-805.
- Di Rosa F, Pabst R. 2005. The bone marrow: A nest for migratory memory t cells. *Trends Immunol.* 26(7):360-366.
- Dutzan N, Konkel JE, Greenwell-Wild T, Moutsopoulos NM. 2016. Characterization of the human immune cell network at the gingival barrier. *Mucosal Immunol.* 9(5):1163-1172.
- Ehmke B, Moter A, Beikler T, Milian E, Flemmig TF. 2005. Adjunctive antimicrobial therapy of periodontitis: Long-term effects on disease progression and oral colonization. *J Periodontol.* 76(5):749-759.
- Farber DL, Netea MG, Radbruch A, Rajewsky K, Zinkernagel RM. 2016. Immunological memory: Lessons from the past and a look to the future. *Nature Reviews Immunology.* 16(2):124-128.
- Fujihashi K, Yamamoto M, Hiroi T, Bamberg TV, McGhee JR, Kiyono H. 1996. Selected th1 and th2 cytokine mrna expression by cd4(+) t cells isolated from inflamed human gingival tissues. *Clin Exp Immunol.* 103(3):422-428.
- Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM et al. 2009. Wnt signaling arrests effector t cell differentiation and generates cd8+ memory stem cells. *Nat Med.* 15(7):808-813.
- Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. 2009. Memory t cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. *Nat Immunol.* 10(5):524-530.
- Geginat J, Lanzavecchia A, Sallusto F. 2003. Proliferation and differentiation potential of human cd8+ memory t-cell subsets in response to antigen or homeostatic cytokines. *Blood.* 101(11):4260-4266.
- Gerlach C, Moseman EA, Loughhead SM, Alvarez D, Zwijnenburg AJ, Waanders L, Garg R, de la Torre JC, von Andrian UH. 2016. The chemokine receptor cx3cr1 defines three antigen-experienced cd8 t cell subsets with distinct roles in immune surveillance and homeostasis. *Immunity.* 45(6):1270-1284.

- Haffajee AD, Cugini MA, Dibart S, Smith C, Kent RL, Jr., Socransky SS. 1997. Clinical and microbiological features of subjects with adult periodontitis who responded poorly to scaling and root planing. *J Clin Periodontol.* 24(10):767-776.
- Hajishengallis G, Darveau RP, Curtis MA. 2012. The keystone-pathogen hypothesis. *Nat Rev Microbiol.* 10(10):717-725.
- Hajishengallis G, Liang S, Payne MA, Hashim A, Jotwani R, Eskan MA, McIntosh ML, Alsam A, Kirkwood KL, Lambris JD et al. 2011. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. *Cell Host Microbe.* 10(5):497-506.
- Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, van Lier RA. 1997. Phenotypic and functional separation of memory and effector human cd8+ t cells. *J Exp Med.* 186(9):1407-1418.
- Harari A, Vallelian F, Pantaleo G. 2004. Phenotypic heterogeneity of antigen-specific cd4 t cells under different conditions of antigen persistence and antigen load. *Eur J Immunol.* 34(12):3525-3533.
- Holmlund A, Lampa E, Lind L. 2017. Poor response to periodontal treatment may predict future cardiovascular disease. *J Dent Res.* 96(7):768-773.
- Hughes FJ, Syed M, Koshy B, Marinho V, Bostanci N, McKay IJ, Curtis MA, Croucher RE, Marcenes W. 2006. Prognostic factors in the treatment of generalized aggressive periodontitis: I. Clinical features and initial outcome. *J Clin Periodontol.* 33(9):663-670.
- Kimura S, Fujimoto N, Okada H. 1991. Impaired autologous mixed-lymphocyte reaction of peripheral blood lymphocytes in adult periodontitis. *Infect Immun.* 59(12):4418-4424.
- Konkel JE, O'Boyle C, Krishnan S. 2019. Distal consequences of oral inflammation. *Front Immunol.* 10(1403).
- Lindhe J, Westfelt E, Nyman S, Socransky SS, Haffajee AD. 1984. Long-term effect of surgical/non-surgical treatment of periodontal disease. *J Clin Periodontol.* 11(7):448-458.
- Mahanonda R, Champaiboon C, Subbalekha K, Sa-Ard-Iam N, Yongyuth A, Isaraphithakkul B, Rerkyen P, Charatkulangkun O, Pichyangkul S. 2018. Memory t cell subsets in healthy gingiva and periodontitis tissues. *J Periodontol.* 89(9):1121-1130.
- Marusina AI, Ono Y, Merleev AA, Shimoda M, Ogawa H, Wang EA, Kondo K, Olney L, Luxardi G, Miyamura Y et al. 2017. Cd4(+) virtual memory: Antigen-inexperienced t cells reside in the naive, regulatory, and memory t cell compartments at similar frequencies, implications for autoimmunity. *J Autoimmun.* 77:76-88.

- Mora JR, von Andrian UH. 2006. T-cell homing specificity and plasticity: New concepts and future challenges. *Trends Immunol.* 27(5):235-243.
- Pihlstrom BL, McHugh RB, Oliphant TH, Ortiz-Campos C. 1983. Comparison of surgical and nonsurgical treatment of periodontal disease. A review of current studies and additional results after 61/2 years. *J Clin Periodontol.* 10(5):524-541.
- Pradeu T, Du Pasquier L. 2018. Immunological memory: What's in a name? *Immunol Rev.* 283(1):7-20.
- Sallusto F, Geginat J, Lanzavecchia A. 2004. Central memory and effector memory t cell subsets: Function, generation, and maintenance. *Annu Rev Immunol.* 22:745-763.
- Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory t lymphocytes with distinct homing potentials and effector functions. *Nature.* 401(6754):708-712.
- Schaberg T, Theilacker C, Nitschke OT, Lode H. 1997. Lymphocyte subsets in peripheral blood and smoking habits. *Lung.* 175(6):387-394.
- Sexton WM, Lin Y, Kryscio RJ, Dawson DR, 3rd, Ebersole JL, Miller CS. 2011. Salivary biomarkers of periodontal disease in response to treatment. *J Clin Periodontol.* 38(5):434-441.
- Seymour GJ, Taubman MA, Eastcott JW, Gemmell E, Smith DJ. 1997. Cd29 expression on cd4+ gingival lymphocytes supports migration of activated memory t lymphocytes to diseased periodontal tissue. *Oral Microbiol Immunol.* 12(3):129-134.
- Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL. 1998. Microbial complexes in subgingival plaque. *J Clin Periodontol.* 25(2):134-144.
- Tanigawa T, Araki S, Nakata A, Kitamura F, Yasumoto M, Sakurai S, Kiuchi T. 1998. Increase in memory (cd4+cd29+ and cd4+cd45ro+) t and naive (cd4+cd45ra+) t-cell subpopulations in smokers. *Arch Environ Health.* 53(6):378-383.
- Tejero JD, Armand NC, Finn CM, Dhume K, Strutt TM, Chai KX, Chen LM, McKinstry KK. 2018. Cigarette smoke extract acts directly on cd4 t cells to enhance th1 polarization and reduce memory potential. *Cell Immunol.* 331:121-129.
- Tonetti MS, Van Dyke TE. 2013. Periodontitis and atherosclerotic cardiovascular disease: Consensus report of the joint efp/aap workshop on periodontitis and systemic diseases. *J Periodontol.* 84(4 Suppl):S24-29.
- van den Broek T, Borghans JAM, van Wijk F. 2018. The full spectrum of human naive t cells. *Nature Reviews Immunology.* 18(6):363-373.
- Van Dyke TE, Bartold PM, Reynolds EC. 2020. The nexus between periodontal inflammation and dysbiosis. *Front Immunol.* 11:511.

- Vardavas CI, Plada M, Tzatzarakis M, Marcos A, Warnberg J, Gomez-Martinez S, Breidenassel C, Gonzalez-Gross M, Tsatsakis AM, Saris WH et al. 2010. Passive smoking alters circulating naive/memory lymphocyte t-cell subpopulations in children. *Pediatr Allergy Immunol.* 21(8):1171-1178.
- Weiss L, Roux A, Garcia S, Demouchy C, Haeffner-Cavaillon N, Kazatchkine MD, Gougeon M-L. 1998. Persistent expansion, in a human immunodeficiency virus-infected person, of v $\beta$ -restricted cd4+ cd8+ t lymphocytes that express cytotoxicity-associated molecules and are committed to produce interferon- $\gamma$  and tumor necrosis factor- $\alpha$ . *The Journal of infectious diseases.* 178(4):1158-1162.
- Zhao L, Zhou Y, Xu Y, Sun Y, Li L, Chen W. 2011. Effect of non-surgical periodontal therapy on the levels of th17/th1/th2 cytokines and their transcription factors in chinese chronic periodontitis patients. *J Clin Periodontol.* 38(6):509-516.

## FIGURE LEGENDS

### **Table 1. Cohort demographics and periodontal parameters.**

† significant difference to health

‡ significant difference to baseline

§ significant difference to 3-months post-treatment

£ – significant difference between good and moderate treatment outcome groups at same timepoint

¢ – significant difference between good and poor treatment outcome groups at same timepoint

¥ – significant difference between moderate and poor treatment outcome groups at same timepoint

Significant Spearman's correlations are represented in bold

Periodontitis subjects ( $n = 8$ , 14.8%) who only contributed to baseline were not assigned to a TxO group.

%BOP, percentage of sites with bleeding on probing; mm, millimetres; PD, probing depth; SD, standard deviation; TxO, treatment outcome;  $\rho$ , Spearman's correlation coefficient

### **Table 2. Variation in red complex bacteria and correlations with periodontal parameters by timepoint.**

† significant difference to health

‡ significant difference to baseline

§ significant difference to 3-months post-treatment

Significant Spearman's correlations are represented in bold

%BOP, percentage of sites with bleeding on probing; PD, probing depth; SD, standard deviation;  $\rho$ , Spearman's correlation coefficient

**Table 3. Correlations between periodontal parameters and memory T-cells by timepoint.**

Spearman's correlation coefficients ( $\rho$ ) between the periodontal parameters, mean probing depth (PD) and percentage of sites with bleeding on probing (%BOP), and naïve ( $T_N$ ), effector memory T-cells re-expressing CD45RA ( $T_{EMRA}$ ), central memory ( $T_{CM}$ ), effector memory ( $T_{EM}$ ) T-cells in  $CD4^+$ ,  $CD8^+$ ,  $CD4^+CD8^+$  and  $CD4^-CD8^-$  cell subsets in health and at baseline, 3-, 6- and 12-months in periodontitis. Significant correlations ( $p \leq 0.05$ ) are represented in bold.

**Figure 1. Gating strategy for phenotyping memory T-cells.**

Lymphocytes were identified based on forward scatter area (FSC-A) and side scatter area (SSC-A). The pan-lymphocyte marker CD45 was used to further isolate lymphocytes. Doublets were excluded using FSC-A and forward scatter height (FSC-H) followed by side scatter width (SSC-W) and SSC-A. T-cells were identified using  $TCR\alpha\beta^+$ , and were further divided into  $CD4^+$ ,  $CD8^+$ ,  $CD4^+CD8^+$  double positive and  $CD4^-CD8^-$  double negative cells. Subsequently,  $CD4^+$ ,  $CD8^+$ ,  $CD4^+CD8^+$  and  $CD4^-CD8^-$  cells were identified as naïve T-cells ( $T_N - CCR7^+CD45RA^+$ ), central memory T-cells ( $T_{CM} - CCR7^+CD45RA^-$ ), effector memory T-cells re-expressing CD45RA ( $T_{EMRA} - CCR7^-CD45RA^+$ ) and effector memory T-cells ( $T_{EM} - CCR7^-CD45RA^-$ ).

**Figure 2.  $T_N$ ,  $T_{EMRA}$ ,  $T_{CM}$  and  $T_{EM}$  cell subsets in  $CD4^+$ ,  $CD8^+$ ,  $CD4^+CD8^+$  and  $CD4^-CD8^-$  cell populations by timepoint.**

$CD4^+$ ,  $CD8^+$ ,  $CD4^+CD8^+$  and  $CD4^-CD8^-$  cells (as a percentage of  $TCR\alpha\beta^+$  cells) **(A)** phenotyped into naïve ( $T_N - CCR7^+CD45RA^+$ ), effector memory T-cells re-expressing CD45RA ( $T_{EMRA} - CCR7^-CD45RA^+$ ), central memory ( $T_{CM} - CCR7^+CD45RA^-$ ) and effector memory ( $T_{EM} - CCR7^-CD45RA^-$ ) T-cells (as a percentage of  $TCR\alpha\beta^+$  and  $CD4^+$ ,  $CD8^+$ ,  $CD4^+CD8^+$  or  $CD4^-CD8^-$  cells) **(B)** in health and periodontitis at baseline, 3-, 6- and 12-months. Box and whisker plots display the median, interquartile range and 10<sup>th</sup> – 90<sup>th</sup> percentile;  $\blacksquare$  above the plots represent  $p \leq 0.05$ . Analysis of significance was calculated using independent samples *t*-test for differences between health and each timepoint in periodontitis, and linear mixed models for variation with timepoint in periodontitis.

**Figure 3. Treatment outcome groups for  $CD4^+ T_N$ ,  $CD4^+ T_{EM}$ ,  $CD8^+ T_N$  and  $CD8^+ T_{EM}$  cells.**

CD4<sup>+</sup> naïve (T<sub>N</sub>) **(A)**, CD4<sup>+</sup> effector memory (T<sub>EM</sub>) **(B)**, CD8<sup>+</sup> T<sub>N</sub> **(C)** and CD8<sup>+</sup> T<sub>EM</sub> **(D)** T-cells as a percentage of TCRαβ<sup>+</sup> and CD4<sup>+</sup> or CD8<sup>+</sup> cells separated based on treatment outcome (TxO) groups as good, moderate and poor in health and periodontitis at baseline, 3-, 6-, and 12-months. Line graphs display the mean and SD and show differences between the three TxO groups; symbols above the plots represent  $p \leq 0.05$  between \* good – moderate, † moderate – poor, ‡ good – poor TxO groups. Box and whisker plots display the median, interquartile ranges and 10<sup>th</sup> – 90<sup>th</sup> percentiles and show differences within the three TxO groups; ◡ above the plots represent  $p \leq 0.05$ . Analysis of significance was calculated using independent samples *t*-test for differences between health and each timepoint in periodontitis, and linear mixed models for variation with timepoint and treatment outcome in periodontitis.

**Figure 4. Treatment outcome groups for red complex bacteria.**

*P. gingivalis* **(A)**, *T. denticola* **(B)** and *T. forsythia* **(C)** (as a percentage of total bacteria) separated based on treatment outcome (TxO) groups as good, moderate and poor in health and periodontitis at baseline, 3-, 6-, and 12-months. Line graphs display the mean and SD and show differences between the three TxO groups; symbols above the plots represent  $p \leq 0.05$  between \* good – moderate, † moderate – poor, ‡ good – poor TxO groups. Box and whisker plots display the median, interquartile ranges and 10<sup>th</sup> – 90<sup>th</sup> percentiles and show differences within the three TxO groups; ◡ above the plots represent  $p \leq 0.05$ . Analysis of significance was calculated using independent samples *t*-test for differences between health and each timepoint in periodontitis, and linear mixed models for variation with timepoint and treatment outcome in periodontitis.

## AUTHOR CONTRIBUTIONS

Nidhi Medara: Conceptualization, Methodology, Investigation, Formal analysis, Visualization, Funding acquisition, Writing - original draft. Jason C. Lenzo: Conceptualization, Methodology, Funding acquisition, Supervision, Writing - review & editing. Katrina A. Walsh: Conceptualization, Methodology, Supervision, Writing - review & editing. James A. Holden: Methodology, Writing - review & editing. Eric C. Reynolds: Conceptualization, Funding acquisition, Writing - review & editing. Ivan B. Darby: Conceptualization, Methodology, Supervision, Funding acquisition, Writing - review & editing. Neil M. O'Brien-Simpson: Conceptualization, Methodology, Supervision, Funding acquisition, Writing – review & editing.

**Table 1. Cohort demographics and periodontal parameters.**

	Health (n = 40)	Periodontitis			
		Baseline (n = 54)	3-months (n = 46)	6-months (n = 44)	12-months (n = 37)
<b>Cohort demographics</b>					
Gender (n, % male)	14 (35.0%)	20 (37.0%)	19 (43.2%)	18 (42.9%)	15 (46.9%)
Age at baseline (years, mean ± SD)	49.30 ± 10.62	53.28 ± 11.44	53.72 ± 11.18	53.70 ± 11.66	54.53 ± 9.70
Smokers (n, %smokers)	6 (15.0%)	15 (27.8%)	12 (26.1%)	10 (22.7%)	7 (18.9%)
Number of teeth (mean ± SD)	26.88 ± 1.40	24.43 ± 2.93 <sup>†</sup>	23.70 ± 3.81 <sup>†‡</sup>	24.03 ± 3.83 <sup>†</sup>	23.44 ± 3.67 <sup>†</sup>
<b>Periodontal parameters separated based on timepoint</b>					
Mean PD (mm, mean ± SD)	2.80 ± 0.28	3.72 ± 0.74 <sup>†</sup>	3.01 ± 0.51 <sup>†‡</sup>	2.92 ± 0.55 <sup>†‡</sup>	2.80 ± 0.44 <sup>†‡§</sup>
%BOP (% mean ± SD)	10.86 ± 7.72	51.61 ± 25.57 <sup>†</sup>	28.35 ± 15.17 <sup>†‡</sup>	25.82 ± 18.84 <sup>†‡</sup>	24.66 ± 18.05 <sup>†‡</sup>
% of sites with PD ≥ 5mm (% mean ± SD)	0.00 ± 0.00	30.41 ± 20.49 <sup>†</sup>	11.90 ± 11.37 <sup>†‡</sup>	10.39 ± 10.36 <sup>†‡</sup>	7.54 ± 7.54 <sup>†‡</sup>
<b>Periodontal parameters separated based on TxO groups</b>					
<b>Mean PD (mm, mean ± SD)</b>					
Good TxO group	2.80 ± 0.28	3.22 ± 0.38 <sup>†£¢</sup> (n = 18, 33.3%)	2.66 ± 0.29 <sup>†‡¢</sup> (n = 18, 39.1%)	2.49 ± 0.23 <sup>†‡¢</sup> (n = 18, 40.9%)	2.41 ± 0.20 <sup>†‡£¢</sup> (n = 14, 37.8%)
Moderate TxO group	2.80 ± 0.28	3.84 ± 0.76 <sup>†¥</sup> (n = 13, 24.1%)	2.99 ± 0.30 <sup>†‡¥</sup> (n = 13, 28.3%)	2.96 ± 0.33 <sup>†‡¥</sup> (n = 12, 27.3%)	2.83 ± 0.21 <sup>†‡¥</sup> (n = 12, 32.4%)
Poor TxO group	2.80 ± 0.28	4.22 ± 0.77 <sup>†</sup> (n = 15, 27.8%)	3.53 ± 0.50 <sup>†‡</sup> (n = 15, 32.6%)	3.48 ± 0.45 <sup>†‡</sup> (n = 14, 31.8%)	3.26 ± 0.36 <sup>†‡</sup> (n = 11, 29.7%)
<b>%BOP (% mean ± SD)</b>					
Good TxO group	10.86 ± 7.72	47.95 ± 22.94 <sup>†</sup> (n = 18)	20.29 ± 11.85 <sup>†‡¢</sup> (n = 18)	17.86 ± 11.37 <sup>†‡¢</sup> (n = 18)	16.67 ± 16.55 <sup>†¢</sup> (n = 14)
Moderate TxO group	10.86 ± 7.72	53.17 ± 31.22 <sup>†</sup> (n = 13)	30.95 ± 15.79 <sup>†‡</sup> (n = 13)	27.26 ± 20.40 <sup>†‡</sup> (n = 12)	26.62 ± 15.87 <sup>†‡</sup> (n = 12)
Poor TxO group	10.86 ± 7.72	53.62 ± 24.61 <sup>†</sup> (n = 15)	38.92 ± 12.92 <sup>†</sup> (n = 15)	38.27 ± 22.67 <sup>†‡</sup> (n = 14)	36.11 ± 18.18 <sup>†</sup> (n = 11)
<b>% of sites with PD ≥ 5mm (% mean ± SD)</b>					
Good TxO group	0.00 ± 0.00	18.64 ± 9.68 <sup>†£¢</sup>	5.54 ± 4.53 <sup>†‡</sup>	3.58 ± 2.59 <sup>†‡</sup>	2.30 ± 2.14 <sup>†‡</sup>

		(n = 18)	(n = 18)	(n = 18)	(n = 14)
<b>Moderate TxO group</b>	0.00 ± 0.00	32.09 ± 21.36 <sup>†</sup>	10.24 ± 4.89 <sup>†‡</sup>	10.12 ± 5.98 <sup>†‡</sup>	7.69 ± 2.92 <sup>†‡</sup>
		(n = 13)	(n = 13)	(n = 12)	(n = 12)
<b>Poor TxO group</b>	0.00 ± 0.00	45.10 ± 24.16 <sup>†</sup>	21.50 ± 14.92 <sup>†‡</sup>	19.67 ± 11.43 <sup>†‡</sup>	14.08 ± 9.70 <sup>†‡</sup>
		(n = 15)	(n = 15)	(n = 14)	(n = 11)

***Spearman's correlations between mean PD and %BOP by timepoint (ρ)***

<b>Mean PD and %BOP</b>	<b>0.517</b>	<b>0.540</b>	<b>0.645</b>	<b>0.623</b>	<b>0.646</b>
-------------------------	--------------	--------------	--------------	--------------	--------------

<sup>†</sup> significant difference to health

<sup>‡</sup> significant difference to baseline

<sup>§</sup> significant difference to 3-months post-treatment

£ – significant difference between good and moderate treatment outcome groups at same timepoint

¢ – significant difference between good and poor treatment outcome groups at same timepoint

¥ – significant difference between moderate and poor treatment outcome groups at same timepoint

Significant Spearman's correlations are represented in bold

Periodontitis subjects (n = 8, 14.8%) who only contributed to baseline were not assigned to a TxO group.

%BOP, percentage of sites with bleeding on probing; mm, millimetres; PD, probing depth; SD, standard deviation; TxO, treatment outcome; ρ, Spearman's correlation coefficient

**Table 2. Variation in red complex bacteria and correlations with periodontal parameters by timepoint.**

	Health (n = 40)	Periodontitis			
		Baseline (n = 54)	3-months (n = 46)	6-months (n = 44)	12-months (n = 37)
<b>Percentage of red complex bacteria as a proportion of total bacteria (mean ± SD)</b>					
<i>P. gingivalis</i>	0.09 ± 0.57	7.81 ± 18.65 <sup>†</sup>	1.71 ± 6.75 <sup>‡</sup>	4.38 ± 15.03	0.25 ± 0.90 <sup>‡</sup>
<i>T. denticola</i>	0.20 ± 0.87	0.75 ± 1.77 <sup>†</sup>	0.67 ± 2.16	0.35 ± 1.15 <sup>‡</sup>	0.34 ± 1.01
<i>T. forsythia</i>	0.21 ± 1.16	0.40 ± 0.67	0.63 ± 1.88	0.27 ± 0.83 <sup>§</sup>	0.29 ± 0.77
<b>Percentage of sites red complex bacteria were recovered from (% detected)</b>					
<i>P. gingivalis</i>	12.5	66.7 <sup>†</sup>	66.7 <sup>†</sup>	64.8 <sup>†</sup>	68.5 <sup>†</sup>
<i>T. denticola</i>	47.5	87.0 <sup>†</sup>	74.1 <sup>†</sup>	88.9 <sup>†</sup>	77.8 <sup>†</sup>
<i>T. forsythia</i>	32.5	90.7 <sup>†</sup>	81.5 <sup>†</sup>	83.3 <sup>†</sup>	77.8 <sup>†</sup>
<b>Spearman's correlations between red complex bacteria and mean PD (ρ)</b>					
<i>P. gingivalis</i>	-0.016	<b>0.299</b>	<b>0.357</b>	0.263	0.050
<i>T. denticola</i>	<b>0.329</b>	0.154	<b>0.341</b>	0.223	0.116
<i>T. forsythia</i>	<b>0.398</b>	<b>0.306</b>	<b>0.356</b>	<b>0.355</b>	0.113
<b>Spearman's correlations between red complex bacteria and %BOP (ρ)</b>					
<i>P. gingivalis</i>	0.130	0.225	<b>0.342</b>	0.269	0.035
<i>T. denticola</i>	<b>0.319</b>	0.233	<b>0.363</b>	0.042	0.099
<i>T. forsythia</i>	<b>0.380</b>	0.185	0.286	0.341	0.149

<sup>†</sup> significant difference to health

<sup>‡</sup> significant difference to baseline

<sup>§</sup> significant difference to 3-months post-treatment

Significant Spearman's correlations are represented in bold

%BOP, percentage of sites with bleeding on probing; PD, probing depth; SD, standard deviation; ρ, Spearman's correlation coefficient

**Table 3. Correlations between periodontal parameters and memory T-cells by timepoint.**

Memory T-cells	Health (n = 40)		Periodontitis							
			Baseline (n = 54)		3-months (n = 46)		6-months (n = 44)		12-months (n = 37)	
	Mean PD	%BOP	Mean PD	%BOP	Mean PD	%BOP	Mean PD	%BOP	Mean PD	%BOP
CD4 <sup>+</sup> cells	0.033	0.129	-0.004	-0.151	-0.077	<b>-0.360</b>	-0.348	<b>-0.487</b>	-0.140	0.049
CD4 <sup>+</sup> T <sub>N</sub> cells	0.022	-0.112	0.199	0.066	-0.017	-0.075	-0.124	0.000	-0.134	-0.161
CD4 <sup>+</sup> T <sub>EMRA</sub> cells	-0.147	<b>-0.360</b>	0.122	0.212	-0.224	-0.155	-0.141	-0.068	-0.237	-0.079
CD4 <sup>+</sup> T <sub>CM</sub> cells	-0.047	0.211	-0.169	-0.055	0.053	0.151	0.085	0.069	-0.081	-0.097
CD4 <sup>+</sup> T <sub>EM</sub> cells	-0.044	-0.103	0.126	0.113	0.058	0.159	0.276	0.186	0.302	0.247
CD8 <sup>+</sup> cells	-0.042	-0.019	-0.059	0.051	0.027	0.324	0.156	<b>0.387</b>	0.214	0.043
CD8 <sup>+</sup> T <sub>N</sub> cells	-0.008	0.109	-0.002	-0.268	-0.075	-0.134	-0.140	-0.040	-0.218	-0.293
CD8 <sup>+</sup> T <sub>EMRA</sub> cells	0.198	-0.052	0.099	<b>0.329</b>	-0.106	-0.101	-0.005	-0.085	0.069	0.018
CD8 <sup>+</sup> T <sub>CM</sub> cells	-0.009	0.055	-0.134	-0.147	0.058	-0.059	0.064	-0.040	-0.189	-0.051
CD8 <sup>+</sup> T <sub>EM</sub> cells	-0.225	-0.131	0.033	0.145	0.223	<b>0.369</b>	0.284	0.254	0.211	<b>0.525</b>
CD4 <sup>+</sup> CD8 <sup>+</sup> cells	-0.191	-0.270	-0.148	-0.150	-0.117	0.125	0.018	0.287	0.022	0.026
CD4 <sup>+</sup> CD8 <sup>+</sup> T <sub>N</sub> cells	-0.017	<b>-0.401</b>	<b>0.324</b>	0.110	0.034	0.231	0.209	0.328	0.009	-0.064
CD4 <sup>+</sup> CD8 <sup>+</sup> T <sub>EMRA</sub> cells	0.173	-0.091	0.078	0.276	-0.054	0.142	0.079	0.140	-0.250	-0.206
CD4 <sup>+</sup> CD8 <sup>+</sup> T <sub>CM</sub> cells	0.058	0.191	-0.118	-0.025	-0.284	<b>-0.505</b>	<b>-0.358</b>	<b>-0.575</b>	-0.269	-0.202
CD4 <sup>+</sup> CD8 <sup>+</sup> T <sub>EM</sub> cells	-0.115	-0.149	0.095	0.125	0.305	<b>0.408</b>	0.183	0.260	0.322	0.317
CD4 <sup>+</sup> CD8 <sup>-</sup> cells	-0.043	0.014	0.074	-0.035	0.014	0.225	0.264	0.371	0.152	<b>0.421</b>
CD4 <sup>+</sup> CD8 <sup>-</sup> T <sub>N</sub> cells	0.070	-0.122	-0.060	-0.214	-0.152	<b>-0.363</b>	-0.057	-0.131	0.013	-0.117
CD4 <sup>+</sup> CD8 <sup>-</sup> T <sub>EMRA</sub> cells	0.083	-0.164	-0.161	<b>-0.321</b>	-0.164	-0.280	-0.306	<b>-0.601</b>	0.046	0.131
CD4 <sup>+</sup> CD8 <sup>-</sup> T <sub>CM</sub> cells	0.119	0.101	0.105	0.136	0.052	<b>0.397</b>	0.202	0.320	-0.054	-0.097
CD4 <sup>+</sup> CD8 <sup>-</sup> T <sub>EM</sub> cells	-0.252	0.154	0.115	0.283	0.126	0.318	0.098	0.331	0.057	0.115

Spearman's correlation coefficients ( $\rho$ ) between the periodontal parameters, mean probing depth (PD) and percentage of sites with bleeding on probing (%BOP), and naïve (T<sub>N</sub>), effector memory T-cells re-expressing CD45RA (T<sub>EMRA</sub>), central memory (T<sub>CM</sub>), effector memory (T<sub>EM</sub>) T-cells in CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup>CD8<sup>+</sup> and CD4<sup>+</sup>CD8<sup>-</sup> cell subsets in health and at baseline, 3-, 6- and 12-months in periodontitis. Significant correlations ( $p \leq 0.05$ ) are represented in bold.




Fig. 1

jcpe\_13399\_f1.tif




Fig. 2

jcpe\_13399\_f2.tif




Fig. 3

jcpe\_13399\_f3.tif




Fig. 4

jcpe\_13399\_f4.tif